SEC Tracker
Get the app

Kinnate Biopharma

Kinnate Biopharma Q1 FY22: net loss $26.9M; diluted EPS −$0.61

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q

Key figures from this report

These are the numbers Kinnate Biopharma reported for Q1 FY22, the quarter ended Mar 31, 2022, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Net income−$26.9MAgainst −$17.5M in Q1 FY2110-Q income statement, on EDGAR
  2. Diluted EPS−$0.61Against −$0.40 in Q1 FY2110-Q income statement, on EDGAR
  3. Cash and cash equivalents$33.1M−82% from $182.4M in Q1 FY21Cash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
  4. Cash from operations−$21.1MAgainst −$13.4M in Q1 FY2110-Q cash flow statement, on EDGAR

View on EDGAR

Open in the app

Get an email when Kinnate Biopharma files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (2834) and public float not reported.

  1. Acura Pharmaceuticals ACUR
  2. Ayala Pharmaceuticals ADXS
  3. Ampio Pharmaceuticals AMPE
  4. Alterity Therapeutics ATHE
  5. Adhera Therapeutics ATRX

Data on this page was fetched . The filing on SEC.gov is the record.